ArticleFrontiers in transplantation2025
Plasma total and donor-derived cell-free DNA predict survival in kidney transplant recipients.
Article in Frontiers in transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rejection-Focused Precision Medicine in Kidney Transplantation: Biology, Biomarkers, and Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Studies evaluating cell-free DNA (cfDNA) in kidney allograft dysfunction have primarily focused on detection of rejection by donor-derived cfDNA (ddcfDNA). The utility of ddcfDNA as a marker of longer-term outcomes has not been examined. Methods: This study investigated the prognostic value of plasma total cfDNA, fractional ddcfDNA and absolute ddcfDNA, quantified in 49 adult kidney transplant recipients (KTRs) at the time of indication allograft biopsy between 2014 and 2017. Primary outcomes were death, death-censored graft loss (DCGL), and all graft loss (AGL). Results: During a median follow-up of 6.3 years, 7 patients died, 7 experienced DCGL, and 14 had AGL. Death was predicted by high total cfDNA [>4,034 copies/ml, hazard ratio (HR) 5.94, 95% CI 1.40-25.13, Discussion: This study demonstrates potential prognostic utility of total cfDNA and fractional ddcfDNA in KTRs with allograft dysfunction. Incorporation of these biomarkers could enhance personalised care, beyond non-invasive detection of rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.